Ascendis Pharma A/S (NASDAQ:ASND) Rating Increased to Overweight at Morgan Stanley

Morgan Stanley upgraded shares of Ascendis Pharma A/S (NASDAQ:ASND) from an equal weight rating to an overweight rating in a research report released on Monday, Marketbeat reports. They currently have $250.00 price target on the biotechnology company’s stock, up from their previous price target of $180.00.

Several other equities analysts have also commented on the stock. UBS Group began coverage on shares of Ascendis Pharma A/S in a report on Tuesday, January 7th. They set a “buy” rating and a $196.00 target price on the stock. Royal Bank of Canada boosted their target price on Ascendis Pharma A/S from $205.00 to $210.00 and gave the company an “outperform” rating in a research note on Friday. Evercore ISI raised their price target on Ascendis Pharma A/S from $260.00 to $280.00 and gave the stock an “outperform” rating in a research report on Friday. Cantor Fitzgerald increased their price objective on Ascendis Pharma A/S from $170.00 to $200.00 and gave the company an “overweight” rating in a research note on Tuesday, February 25th. Finally, JPMorgan Chase & Co. upped their price target on shares of Ascendis Pharma A/S from $200.00 to $245.00 and gave the company an “overweight” rating in a report on Friday. One research analyst has rated the stock with a hold rating and fifteen have given a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $216.07.

Ascendis Pharma A/S Price Performance

Shares of Ascendis Pharma A/S stock opened at $170.74 on Monday. Ascendis Pharma A/S has a 1 year low of $111.09 and a 1 year high of $183.00. The firm has a market cap of $10.41 billion, a PE ratio of -24.05 and a beta of 0.41. The company has a 50 day simple moving average of $155.67 and a two-hundred day simple moving average of $140.71.

Ascendis Pharma A/S (NASDAQ:ASND) last released its earnings results on Thursday, May 1st. The biotechnology company reported ($1.66) EPS for the quarter, missing analysts’ consensus estimates of ($1.56) by ($0.10). The company had revenue of $123.97 million during the quarter, compared to analyst estimates of $98.56 million. As a group, research analysts anticipate that Ascendis Pharma A/S will post -4.34 earnings per share for the current year.

Hedge Funds Weigh In On Ascendis Pharma A/S

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of Ascendis Pharma A/S in the 4th quarter worth about $28,000. Wilmington Savings Fund Society FSB purchased a new position in Ascendis Pharma A/S during the third quarter valued at $30,000. Jones Financial Companies Lllp increased its position in shares of Ascendis Pharma A/S by 394.0% during the fourth quarter. Jones Financial Companies Lllp now owns 247 shares of the biotechnology company’s stock valued at $34,000 after acquiring an additional 197 shares in the last quarter. Blue Trust Inc. increased its position in Ascendis Pharma A/S by 415.2% during the fourth quarter. Blue Trust Inc. now owns 407 shares of the biotechnology company’s stock valued at $56,000 after acquiring an additional 328 shares during the last quarter. Finally, GAMMA Investing LLC grew its position in shares of Ascendis Pharma A/S by 58.0% during the 4th quarter. GAMMA Investing LLC now owns 583 shares of the biotechnology company’s stock valued at $80,000 after acquiring an additional 214 shares during the period.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.